According to our (Global Info Research) latest study, the global Hetrombopag Ethanolamine market size was valued at US$ 250 million in 2025 and is forecast to a readjusted size of US$ 625 million by 2032 with a CAGR of 10.6% during review period.
In 2025, global Herombopag Ethanolamine production reached approximately 165,000 units.Hetrombopag Ethanolamine is an orally administered small-molecule thrombopoietin receptor agonist (TPO-RA), primarily used for the treatment of thrombocytopenia-related disorders. It is the ethanolamine salt form of hetrombopag and works by selectively activating the thrombopoietin receptor (c-Mpl), thereby promoting the proliferation and differentiation of megakaryocytes and increasing platelet production.Clinically, the drug is mainly used for the treatment of conditions such as primary immune thrombocytopenia (ITP), effectively improving platelet counts and reducing the risk of bleeding. Compared with traditional therapies, hetrombopag ethanolamine offers advantages including convenient oral administration, stable efficacy, and a favorable safety profile.As one of the innovative drugs independently developed in China, it demonstrates promising application prospects in the treatment of hematological diseases.
Hetrombopag Ethanolamine, as an orally administered thrombopoietin receptor agonist (TPO-RA) independently developed in China, is primarily positioned in the treatment market for thrombocytopenia, particularly addressing clear clinical needs in indications such as primary immune thrombocytopenia (ITP). With the acceleration of population aging, the rising incidence of thrombocytopenia associated with cancer therapies, and increasing attention to bleeding risk management, the global thrombocytopenia treatment market continues to expand, providing stable growth opportunities for this drug. From a competitive perspective, existing therapies such as eltrombopag and romiplostim have already captured a certain market share; however, their relatively high cost or limitations in administration routes (e.g., injection) create opportunities for next-generation oral agents with improved safety profiles.
In the Chinese market, government support for innovative drugs, the continuous improvement of reimbursement negotiation mechanisms, and enhanced patient accessibility are expected to facilitate the market penetration of hetrombopag ethanolamine. Meanwhile, with the gradual updates of clinical guidelines and increasing physician awareness of TPO-RA therapies, its role in standardized treatment is likely to be further strengthened. From a global perspective, demand for treatments in hematological diseases continues to grow; however, expansion into international markets will still require additional clinical evidence and progress in regulatory approvals.
This report is a detailed and comprehensive analysis for global Hetrombopag Ethanolamine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Hetrombopag Ethanolamine market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Hetrombopag Ethanolamine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Hetrombopag Ethanolamine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Hetrombopag Ethanolamine market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Hetrombopag Ethanolamine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Hetrombopag Ethanolamine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Jiangsu Hengrui Pharmaceuticals, Luzsana Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Hetrombopag Ethanolamine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
2.5 mg/tablet
5 mg/tablet
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Dosage Form
Tablets
Powder
Market segment by Application
Primary Immune Thrombocytopenia (ITP)
Cancer Therapy–related Thrombocytopenia
Aplastic Anemia (AA)
Others
Major players covered
Jiangsu Hengrui Pharmaceuticals
Luzsana Biotechnology
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hetrombopag Ethanolamine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Hetrombopag Ethanolamine, with price, sales quantity, revenue, and global market share of Hetrombopag Ethanolamine from 2021 to 2026.
Chapter 3, the Hetrombopag Ethanolamine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hetrombopag Ethanolamine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Hetrombopag Ethanolamine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Hetrombopag Ethanolamine.
Chapter 14 and 15, to describe Hetrombopag Ethanolamine sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Hetrombopag Ethanolamine. Industry analysis & Market Report on Hetrombopag Ethanolamine is a syndicated market report, published as Global Hetrombopag Ethanolamine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Hetrombopag Ethanolamine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.